{"filing":{"accession_number":"0001104659-26-079871","cik":"0001087294","ticker":"CPIX","company_name":"CUMBERLAND PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"tm2619330d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1087294/000110465926079871/tm2619330d1_8k.htm"},"events":[{"id":15502,"run_id":13829,"accession_number":"0001104659-26-079871","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.96,"summary":"Cumberland Pharmaceuticals completed the sale of its branded pharmaceutical business to Apotex and affiliates for $100 million in cash on July 1, 2026, following shareholder approval on June 24, 2026 with 99% support. The transaction fundamentally restructures the company to focus on its rare disease pipeline, eliminating substantially all revenue-generating operations. Amendment No. 1 to the acquisition agreement excluded certain contracts from the transferred assets, and the related credit facility was terminated upon closing.","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13303,"accession_number":"0001104659-26-079871","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Cumberland Pharmaceuticals entered into Amendment No. 1 to an existing agreement with Nuvo (a subsidiary of Apotex) to exclude certain contracts from the assets being transferred. The supplemental exhibits confirm this is the closing of a $100 million strategic transaction where Apotex acquired Cumberland's branded pharmaceuticals business, with shareholder approval (99% in favor). This constitutes a material disposition/change of control event under Item 1.01, fundamentally restructuring the company to focus on its rare disease pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13304,"accession_number":"0001104659-26-079871","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.02 discloses termination of a material credit facility in connection with \"the closing of the Transaction,\" which the press release (EX-99.1) identifies as Apotex's acquisition of Cumberland's branded pharmaceutical business for $100 million in cash. This is a material disposition/change of control event. The credit facility termination is incidental to the primary M\u0026A transaction, which involved shareholder approval (99%+ votes in favor) and a strategic shift toward rare disease pipeline development. The pro forma financials (EX-99.2) confirm the transaction eliminated substantially all revenue-generating operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13305,"accession_number":"0001104659-26-079871","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Cumberland Pharmaceuticals completed the sale of its branded pharmaceutical assets to Apotex and affiliates for $100 million cash consideration on the Closing Date (July 1, 2026), following shareholder approval on June 24, 2026. This is a material disposition of assets that fundamentally restructures the company's operations, shifting focus from branded pharmaceuticals to rare disease pipeline development. The transaction is disclosed under Item 2.01 (Completion of Acquisition or Disposition of Assets) and includes pro forma financial statements showing the elimination of substantially all revenue-generating operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13306,"accession_number":"0001104659-26-079871","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 5.02 discloses the resignation of two officers (Chris T. Bitterman, VP Sales \u0026 Marketing, and James L. Herman, VP Trade \u0026 Distribution and Corporate Compliance Officer) effective July 31, 2026, in connection with the closing of a transaction with Apotex. However, the supplemental exhibits reveal this is part of a material acquisition/disposition: Cumberland sold its branded pharmaceutical business to Apotex for $100 million, which was approved by shareholders with 99% support. The officer departures are incidental to the larger M\u0026A transaction. The pro forma financials show the transaction eliminates substantially all product revenues and related operations, representing a fundamental strategic shift. While Item 5.02 technically covers the departures, the material event is the completed M\u0026A transaction disclosed in the press release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13307,"accession_number":"0001104659-26-079871","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure announces the closing of a material acquisition/disposition transaction whereby Apotex acquired Cumberland's branded pharmaceutical business for $100 million in cash, following shareholder approval with over 99% support. The press release and pro forma financial statements confirm this is a significant strategic transaction that fundamentally reshapes Cumberland's business focus from branded pharmaceuticals to rare disease pipeline development. This constitutes a material disposition/change of control event under the ma_activity category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13303,"accession_number":"0001104659-26-079871","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Cumberland Pharmaceuticals entered into Amendment No. 1 to an existing agreement with Nuvo (a subsidiary of Apotex) to exclude certain contracts from the assets being transferred. The supplemental exhibits confirm this is the closing of a $100 million strategic transaction where Apotex acquired Cumberland's branded pharmaceuticals business, with shareholder approval (99% in favor). This constitutes a material disposition/change of control event under Item 1.01, fundamentally restructuring the company to focus on its rare disease pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-07-01"},{"id":13304,"accession_number":"0001104659-26-079871","item_number":"1.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Item 1.02 discloses termination of a material credit facility in connection with \"the closing of the Transaction,\" which the press release (EX-99.1) identifies as Apotex's acquisition of Cumberland's branded pharmaceutical business for $100 million in cash. This is a material disposition/change of control event. The credit facility termination is incidental to the primary M\u0026A transaction, which involved shareholder approval (99%+ votes in favor) and a strategic shift toward rare disease pipeline development. The pro forma financials (EX-99.2) confirm the transaction eliminated substantially all revenue-generating operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-07-01"},{"id":13305,"accession_number":"0001104659-26-079871","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Cumberland Pharmaceuticals completed the sale of its branded pharmaceutical assets to Apotex and affiliates for $100 million cash consideration on the Closing Date (July 1, 2026), following shareholder approval on June 24, 2026. This is a material disposition of assets that fundamentally restructures the company's operations, shifting focus from branded pharmaceuticals to rare disease pipeline development. The transaction is disclosed under Item 2.01 (Completion of Acquisition or Disposition of Assets) and includes pro forma financial statements showing the elimination of substantially all revenue-generating operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-07-01"},{"id":13306,"accession_number":"0001104659-26-079871","item_number":"5.02","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Item 5.02 discloses the resignation of two officers (Chris T. Bitterman, VP Sales \u0026 Marketing, and James L. Herman, VP Trade \u0026 Distribution and Corporate Compliance Officer) effective July 31, 2026, in connection with the closing of a transaction with Apotex. However, the supplemental exhibits reveal this is part of a material acquisition/disposition: Cumberland sold its branded pharmaceutical business to Apotex for $100 million, which was approved by shareholders with 99% support. The officer departures are incidental to the larger M\u0026A transaction. The pro forma financials show the transaction eliminates substantially all product revenues and related operations, representing a fundamental strategic shift. While Item 5.02 technically covers the departures, the material event is the completed M\u0026A transaction disclosed in the press release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-07-01"},{"id":13307,"accession_number":"0001104659-26-079871","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The Item 8.01 disclosure announces the closing of a material acquisition/disposition transaction whereby Apotex acquired Cumberland's branded pharmaceutical business for $100 million in cash, following shareholder approval with over 99% support. The press release and pro forma financial statements confirm this is a significant strategic transaction that fundamentally reshapes Cumberland's business focus from branded pharmaceuticals to rare disease pipeline development. This constitutes a material disposition/change of control event under the ma_activity category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T20:17:24.954177+00:00","company_name":"CUMBERLAND PHARMACEUTICALS INC","ticker":"CPIX","filing_date":"2026-07-01"}]}